BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 26707054)

  • 1. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
    Jacobs IJ; Menon U; Ryan A; Gentry-Maharaj A; Burnell M; Kalsi JK; Amso NN; Apostolidou S; Benjamin E; Cruickshank D; Crump DN; Davies SK; Dawnay A; Dobbs S; Fletcher G; Ford J; Godfrey K; Gunu R; Habib M; Hallett R; Herod J; Jenkins H; Karpinskyj C; Leeson S; Lewis SJ; Liston WR; Lopes A; Mould T; Murdoch J; Oram D; Rabideau DJ; Reynolds K; Scott I; Seif MW; Sharma A; Singh N; Taylor J; Warburton F; Widschwendter M; Williamson K; Woolas R; Fallowfield L; McGuire AJ; Campbell S; Parmar M; Skates SJ
    Lancet; 2016 Mar; 387(10022):945-956. PubMed ID: 26707054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
    Menon U; Gentry-Maharaj A; Burnell M; Singh N; Ryan A; Karpinskyj C; Carlino G; Taylor J; Massingham SK; Raikou M; Kalsi JK; Woolas R; Manchanda R; Arora R; Casey L; Dawnay A; Dobbs S; Leeson S; Mould T; Seif MW; Sharma A; Williamson K; Liu Y; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Jacobs IJ; Parmar M
    Lancet; 2021 Jun; 397(10290):2182-2193. PubMed ID: 33991479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
    Menon U; Gentry-Maharaj A; Burnell M; Ryan A; Kalsi JK; Singh N; Dawnay A; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Parmar M; Jacobs IJ
    Health Technol Assess; 2023 May; ():1-81. PubMed ID: 37183782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Menon U; Gentry-Maharaj A; Hallett R; Ryan A; Burnell M; Sharma A; Lewis S; Davies S; Philpott S; Lopes A; Godfrey K; Oram D; Herod J; Williamson K; Seif MW; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso NN; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Singh N; Dawnay A; Skates SJ; Parmar M; Jacobs I
    Lancet Oncol; 2009 Apr; 10(4):327-40. PubMed ID: 19282241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Menon U; McGuire AJ; Raikou M; Ryan A; Davies SK; Burnell M; Gentry-Maharaj A; Kalsi JK; Singh N; Amso NN; Cruickshank D; Dobbs S; Godfrey K; Herod J; Leeson S; Mould T; Murdoch J; Oram D; Scott I; Seif MW; Williamson K; Woolas R; Fallowfield L; Campbell S; Skates SJ; Parmar M; Jacobs IJ
    Br J Cancer; 2017 Aug; 117(5):619-627. PubMed ID: 28742794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial.
    Menon U; Gentry-Maharaj A; Burnell M; Ryan A; Singh N; Manchanda R; Kalsi JK; Woolas R; Arora R; Casey L; Dawnay A; Sharma A; Williamson K; Apostolidou S; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Jacobs IJ; Parmar MKB
    Lancet Oncol; 2023 Sep; 24(9):1018-1028. PubMed ID: 37657461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Moss HA; Berchuck A; Neely ML; Myers ER; Havrilesky LJ
    JAMA Oncol; 2018 Feb; 4(2):190-195. PubMed ID: 29222541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation.
    Kearns B; Chilcott J; Whyte S; Preston L; Sadler S
    BMC Med; 2016 Dec; 14(1):200. PubMed ID: 27919292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening.
    Pavlik EJ
    Womens Health (Lond); 2016 Sep; 12(5):475-479. PubMed ID: 27595999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT.
    Fallowfield L; Solis-Trapala I; Menon U; Langridge C; May S; Jacobs I; Jenkins V
    Br J Cancer; 2017 Apr; 116(8):1111-1117. PubMed ID: 28324886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.
    Duffy S; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith R; Evans A; Blyuss O; Johns L; Ellis I; Sasieni P; Wale C; Myles J; Moss S
    Health Technol Assess; 2020 Oct; 24(55):1-24. PubMed ID: 33141657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses.
    Gentry-Maharaj A; Burnell M; Dilley J; Ryan A; Karpinskyj C; Gunu R; Mallett S; Deeks J; Campbell S; Jacobs I; Sundar S; Menon U
    Am J Obstet Gynecol; 2020 Jan; 222(1):56.e1-56.e17. PubMed ID: 31351062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population.
    Blyuss O; Burnell M; Ryan A; Gentry-Maharaj A; Mariño IP; Kalsi J; Manchanda R; Timms JF; Parmar M; Skates SJ; Jacobs I; Zaikin A; Menon U
    Clin Cancer Res; 2018 Oct; 24(19):4726-4733. PubMed ID: 30084833
    [No Abstract]   [Full Text] [Related]  

  • 14. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Henderson JT; Webber EM; Sawaya GF
    JAMA; 2018 Feb; 319(6):595-606. PubMed ID: 29450530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of transvaginal ultrasound in screening for ovarian cancer.
    Campbell S; Gentry-Maharaj A
    Climacteric; 2018 Jun; 21(3):221-226. PubMed ID: 29490504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.
    Pinsky PF; Zhu C; Skates SJ; Black A; Partridge E; Buys SS; Berg CD
    Int J Cancer; 2013 May; 132(9):2127-33. PubMed ID: 23065684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.
    Menon U; Ryan A; Kalsi J; Gentry-Maharaj A; Dawnay A; Habib M; Apostolidou S; Singh N; Benjamin E; Burnell M; Davies S; Sharma A; Gunu R; Godfrey K; Lopes A; Oram D; Herod J; Williamson K; Seif MW; Jenkins H; Mould T; Woolas R; Murdoch JB; Dobbs S; Amso NN; Leeson S; Cruickshank D; Scott I; Fallowfield L; Widschwendter M; Reynolds K; McGuire A; Campbell S; Parmar M; Skates SJ; Jacobs I
    J Clin Oncol; 2015 Jun; 33(18):2062-71. PubMed ID: 25964255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials.
    Menon U; Gentry-Maharaj A; Burnell M; Apostolidou S; Ryan A; Kalsi JK; Singh N; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Dawnay A; Parmar M; Jacobs IJ;
    Health Technol Assess; 2023 Aug; ():1-38. PubMed ID: 37843101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Dilley J; Gentry-Maharaj A; Ryan A; Burnell M; Manchanda R; Kalsi J; Singh N; Woolas R; Sharma A; Williamson K; Mould T; Fallowfield L; Campbell S; Skates SJ; McGuire A; Parmar M; Jacobs I; Menon U
    Gynecol Oncol; 2023 Dec; 179():123-130. PubMed ID: 37980767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
    Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
    Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.